Aug 9, 2022 08:00AM
May 19, 2022 04:30PM
May 17, 2022 08:04AM
May 17, 2022 08:00AM
Mar 9, 2022 08:00AM
Feb 24, 2022 08:00AM
Feb 14, 2022 08:00AM CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
Dec 21, 2021 08:00AM
Nov 12, 2021 08:00AM
Nov 2, 2021 08:00AM
Oct 14, 2021 08:00AM
Aug 24, 2021 08:00AM
Aug 12, 2021 04:06PM
Jul 29, 2021 08:00AM CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
Jul 16, 2021 08:00AM
Jul 13, 2021 08:00AM
Jun 30, 2021 08:00AM
Jun 18, 2021 04:30PM
May 13, 2021 08:00AM
May 7, 2021 04:00PM
Apr 1, 2021 04:30PM CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis
Mar 25, 2021 08:00AM
Mar 8, 2021 08:00AM
Mar 4, 2021 08:00AM
Jan 15, 2021 08:00AM
Dec 31, 2020 02:00PM
Dec 7, 2020 08:00AM
Nov 16, 2020 08:00AM CytRx Comments on Quarterly Results and Recent Strategic Progress
Nov 11, 2020 08:00AM
Oct 27, 2020 08:00AM
Oct 13, 2020 08:00AM
Oct 7, 2020 08:00AM
Sep 30, 2020 08:00AM
Sep 17, 2020 08:00AM
Aug 10, 2020 08:00AM CytRx Files Definitive Proxy Statement and Sends Letter to Stockholders
Jul 21, 2020 09:03AM
Jul 21, 2020 09:00AM
Jul 20, 2020 09:00AM
Jun 29, 2020 09:00AM
Jun 1, 2020 09:00AM
May 26, 2020 09:09AM
May 26, 2020 09:00AM CytRx Corporation Highlights Orphazyme's Receipt of FDA Fast Track Designation for the Development of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
May 21, 2020 09:00AM
Feb 4, 2020 09:00AM
Dec 19, 2019 09:00AM
Aug 9, 2019 09:00AM
Jul 30, 2019 09:00AM
Jun 19, 2019 09:00AM
May 15, 2019 09:00AM CytRx Corporation Reports First Quarter 2019 Financial Results
May 2, 2019 09:00AM

323,900 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All